Teva

News

Lilly files new class migraine drug with FDA

Eli Lilly has filed a new migraine drug, lasmiditan, with the US regulator, the first drug in its class to be reviewed as a treatment for the condition.

News

Sandoz axes filing of US Rituxan biosimilar

Sandoz has abandoned plans to get a cheaper biosimilar of Swiss rival Roche’s cancer drug Rituxan (rituximab) approved in the US.

News

Teva slumps after Express Scripts funds migraine rivals in U...

A major prescription benefit manager in the US will not reimburse Teva’s preventative migraine drug Ajovy (fremanezumab), in an effort to cut costs.

News

Celltrion/Teva Rituxan biosimilar edges closer to US approva...

It looks increasingly likely that Roche’s cancer blockbuster Rituxan (rituximab) will face competition from a cheaper biosimilar in the coming months after backing from an FDA expert commit

News

Lilly pushes into migraine market as Emgality approved in US

The FDA has approved Eli Lilly’s Emgality (galcanezumab) for migraine prevention in adults, the third in a group of new class of drugs for the condition.

News

FDA approves Teva's migraine drug, decision due on Lilly's r...

The FDA has finally approved Teva’s potential blockbuster migraine drug Ajovy after months of delays due to concerns about the manufacturing plant operated by the company’s partner, Celltri

Lilly files new class migraine drug with FDA

Sandoz axes filing of US Rituxan biosimilar

Teva slumps after Express Scripts funds migraine rivals in U...

Celltrion/Teva Rituxan biosimilar edges closer to US approva...

Lilly pushes into migraine market as Emgality approved in US

FDA approves Teva's migraine drug, decision due on Lilly's r...

CHMP decision levels the playing field for GSK's RSV jab

How to meet your physicians where they are online

Teva

Editor's Picks